Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505317 | PMC |
Basic Clin Pharmacol Toxicol
February 2025
Department of Addiction Psychiatry, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan City, Taiwan.
Intern Emerg Med
January 2025
Department of Internal Medicine, Ospedale Fatebenefratelli, ASST Fatebenefratelli-Sacco, Piazzale Principessa Clotilde n 3, 20121, Milan, Italy.
Sports Med Open
January 2025
Université de Pau et des Pays de l'Adour, E2S, MEPS, ZA Bastillac Sud, 11 rue Morane Saulnier, Tarbes, 65000, France.
Eur J Cancer
January 2025
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address:
Groundbreaking studies have reshaped the treatment landscape for patients with resectable stage ≥IIIB melanoma by demonstrating the benefits of neoadjuvant therapy. Data from the NADINA and SWOG S1801 trials reveal substantial improvements in event-free survival compared to adjuvant therapy alone. These studies employed distinct neoadjuvant immunotherapy approaches - ipilimumab plus nivolumab in NADINA and anti-PD-1 monotherapy in SWOG S1801 - highlighting potential differences in efficacy and toxicity.
View Article and Find Full Text PDFNeuro Oncol
January 2025
Department of Neurosurgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871 Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!